title: Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
abstract: OBJECTIVE
  To compare serum chromogranin A (CgA) and insulin-like growth factor 1 (IGF-1) with the classical prostate-specific antigen (PSA) marker in clinically localized prostate adenocarcinomas.
  
  
  METHODS
  This is a prospective single-center study that included 64 consecutive men with newly diagnosed clinically localized prostate adenocarcinoma and 20 consecutive men with histologically confirmed benign prostatic hyperplasia (BPH). A blood sample for the determination of serum total PSA, CgA and IGF-1 levels (RIA) was obtained from all cases. Analysis of variance was performed to evaluate their variations according to disease and the pathological characteristics of prostate adenocarcinoma.
  
  
  RESULTS
  Only serum PSA levels (p < 0.0001) and not IGF-1 (p = 0.5475) or CgA (p = 0.5043) were significantly higher in the prostate cancer (PCa) group as compared to the BPH group. A significant variance between BPH and PCa divided on the basis of pT stage was found for PSA levels (p < 0.0001) but not for CgA (p = 0.0869) and IGF-1 (p = 0.6883) levels. Dividing PCa on the basis of Gleason score, a significant variance was found for CgA (p = 0.0100) and for PSA (p < 0.001), but not for IGF-1 (p = 0.6895) levels.
  
  
  CONCLUSIONS
  In our population the quantification of PSA and CgA serum levels and not of IGF-1 provides independent significant information in the diagnosis and aggressiveness of PCa, respectively.
authors.affiliation: Department of Urology, University of Rome, Rome, Italy. sciarrajr@hotmail.com
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sciarra
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Gentile
authors.forename: Salvatori
authors.initials: S
authors.lastname: Monti
authors.forename: Cristian
authors.initials: C
authors.lastname: Dattilo
authors.forename: Anna
authors.initials: A
authors.lastname: Autran Gomez
authors.forename: Stefano
authors.initials: S
authors.lastname: Salciccia
authors.forename: Laura Proietti
authors.initials: LP
authors.lastname: Pannunzi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Toscano
authors.forename: Franco
authors.initials: F
authors.lastname: Di Silverio
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000175:diagnosis; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D053379:Chromogranin A / Q000097:blood*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000096:biosynthesis*; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D012016:Reference Values
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A; D007334:Insulin-Like Growth Factor I; D017430:Prostate-Specific Antigen